
Catherine E Simpson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3539055/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ventricular mass discriminates pulmonary arterial hypertension as redefined at the SixthÂWorld Symposium on Pulmonary Hypertension. Pulmonary Circulation, 2022, 12, e12005.	1.7	3
2	Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. ERJ Open Research, 2022, 8, 00002-2022.	2.6	8
3	Promises and Pitfalls of Multiomics Approaches to Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1377-1379.	5.6	1
4	<i>COL18A1</i> genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study. ERJ Open Research, 2022, 8, 00725-2021.	2.6	1
5	A novel approach to perioperative risk assessment for patients with pulmonary hypertension. ERJ Open Research, 2021, 7, 00257-2021.	2.6	6
6	ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. Chest, 2021, 160, 297-306.	0.8	6
7	The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. ERJ Open Research, 2021, 7, 00378-2021.	2.6	5
8	Right ventricular function as assessed by cardiac magnetic resonance imagingâ€derived strain parameters compared to highâ€fidelity micromanometer catheter measurements. Pulmonary Circulation, 2021, 11, 1-10.	1.7	4
9	Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease–Associated Pulmonary Hypertension. Journal of the American Heart Association, 2021, 10, e021409.	3.7	5
10	Performance of Critical Care Outcome Prediction Models in an Intermediate Care Unit. Journal of Intensive Care Medicine, 2020, 35, 1529-1535.	2.8	4
11	Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Medicine, 2020, 18, 268.	5.5	15
12	Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. Journal of Pediatrics, 2020, 223, 164-169.e1.	1.8	9
13	Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension. European Respiratory Journal, 2020, 55, 1901761.	6.7	48
14	Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. Chest, 2020, 157, 1606-1616.	0.8	20
15	Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosisâ€related pulmonary arterial hypertension. Pulmonary Circulation, 2019, 9, 1-9.	1.7	32
16	Ventricular mass as a prognostic imaging biomarker in incident pulmonary arterial hypertension. European Respiratory Journal, 2019, 53, 1802067.	6.7	22
17	Myocardial Fibrosis as a Potential Maladaptive Feature of Right Ventricle Remodeling in Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 662-663.	5.6	12
18	Non–Cystic Fibrosis Bronchiectasis: Microbiology, Clinical Outcomes, and Pharmacotherapy Practices. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 651-653.	5.6	1

#	Article	IF	CITATIONS
19	Hospital mortality prediction for intermediate care patients: Assessing the generalizability of the Intermediate Care Unit Severity Score (IMCUSS). Journal of Critical Care, 2018, 46, 94-98.	2.2	12
20	Outcomes of Emergency Medical Patients Admitted to an Intermediate Care Unit With Detailed Admission Guidelines. American Journal of Critical Care, 2017, 26, e1-e10.	1.6	16